Retension Pharmaceuticals, Inc. (RTSN)
NASDAQ
Closed
Oct 20, 2026
Day's Range
15.3352 wk Range
9.66Overview - RTSN - Retension Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
24.07M
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Ownership
Shares Outstanding
8.33M
Float
680.63K
Held by Insiders
‪18.26%‬
Held by Institutions
‪0.00%‬
Price stats
50-Day Avg
‪11.28‬
200-Day Avg
‪11.28‬
Market Cap - RTSN - Retension Pharmaceuticals, Inc.
Peers - RTSN - Retension Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- RTSNNASDAQRetension Pharmaceuticals, Inc.117.22MMarket Cap+25.16%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.72BMarket Cap+5.31%52-week change148.09P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - RTSN - Retension Pharmaceuticals, Inc.
About
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and related cardiovascular disorders. Its lead product candidate, RTN-001, is an orally administered, once-daily PDE5 inhibitor being evaluated for patients with uncontrolled or resistant…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
